News release from last Friday indicated that they had now enrolled just over 1200 patients. If you read my previous message, I give you a good idea of the expected MACE rates. The EXAMINE trial is what Dr. Michael Sweeney described BETonMACE as being modeled after; however, BETonMACE will likely be a bit higher event rate because of low-HDL as I describe as well. You have a good point about the DSMB delay in reporting and confirming MACE.
BearDownAZ
